Search research articles
Contact Us
Filters
Showing results (161-170 of 168) with videos related to
Page
of 17
Sort By:
You have reached the last page of results.
This site can display upto 168 results.
Clinical Breast Cancer
|
September 28, 2019
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022
Rachel A Freedman, Rebecca S Gelman, Nathalie Y R Agar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.
Nature Medicine
|
June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
The Lancet. Oncology
|
November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Nature Medicine
|
June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
JCO Precision Oncology
|
May 4, 2023
A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
Jamie O Brett, Taronish D Dubash, Gabriela N Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2019
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A Freedman, Rebecca S Gelman, Carey K Anders, et al.
The Oncologist
|
August 13, 2022
Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization
Andrew G Shuman, Matti S Aapro, Benjamin Anderson, et al.
Page
of 17
Search research articles
Search
Showing results (161-170 of 168) with videos related to
Sort By:
Page
of 17
You have reached the last page of results.
This site can display upto 168 results.
Clinical Breast Cancer
|
September 28, 2019
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022
Rachel A Freedman, Rebecca S Gelman, Nathalie Y R Agar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.
Nature Medicine
|
June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
The Lancet. Oncology
|
November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Nature Medicine
|
June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
JCO Precision Oncology
|
May 4, 2023
A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
Jamie O Brett, Taronish D Dubash, Gabriela N Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2019
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A Freedman, Rebecca S Gelman, Carey K Anders, et al.
The Oncologist
|
August 13, 2022
Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization
Andrew G Shuman, Matti S Aapro, Benjamin Anderson, et al.
Page
of 17